Clinical trialNCT07428044RecruitingPhase 2Interventional

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

SponsorMemorial Sloan Kettering Cancer CenterEnrollment14Non-Small Cell Lung CancerNon-Small Cell Lung Cancer Stage IIIANon-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage II

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

James Isbell, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Centre Hospitalier de L'Université de Montreal (data Collection Only)
Montreal, Quebec, Canada
Not, yet, recruiting

United States

University of Michigan (data Collection Only)
Ann Arbor, Michigan, United States
Not, yet, recruiting
Mayo Clinic (data Collection Only)
Rochester, Minnesota, United States
Not, yet, recruiting
Memorial Sloan Kettering Basking Ridge (limited Protocol Activities)
Basking Ridge, New Jersey, United States
Recruiting
Memorial Sloan Kettering Monmouth (limited Protocol Activities)
Middletown, New Jersey, United States
Recruiting
Memorial Sloan Kettering Bergen (limited Protocol Activities)
Montvale, New Jersey, United States
Recruiting
Memorial Sloan Kettering Suffolk-Commack (limited Protocol Activities)
Commack, New York, United States
Recruiting
Memorial Sloan Kettering Westchester (limited Protocol Activities)
Harrison, New York, United States
Recruiting
Memorial Sloan Kettering Cancer Center (all Protocol Activites)
New York, New York, United States
Recruiting
Memorial Sloan Kettering Nassau (limited Protocol Activites)
Rockville Centre, New York, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Trastuzumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Feb 2026
Primary completion: 13 Feb 2027
Completion: 13 Feb 2027
Last update posted: 23 Feb 2026
Registered enrollment: 14
Registry id: NCT07428044

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.